Objective To detect the levels of Krebs von den lungen 6 (KL-6) in bronchoalveolar lavage fluid (BALF) and serum of patients with idiopathic pulmonary fibrosis (IPF),and explore its clinical significance.
Methods Thirty-four patients with IPF and 10 patients with sarcoidosis in Ⅰ period were recruited in the study. ELISA was used to detect the level of KL-6 in BALF and serum.
Results In the IPF group,the forced vital capacity as percentage of predicted value (FVC% pred) and diffusion capacity for carbon monoxide as percentage of predicted value (DLCO %pred) were both significantly lower than those of the sarcoidosis group[(69.51±13.65)% vs. (82.06±5.84)%,(48.58±12.73)% vs. (81.47±6.39)%,P<0.01]. In the BALF of IPF group,the percentage of neutrophils was higher[(8.91±6.79)% vs. (5.50±3.60)%,P<0.05],and the percentages of lymphocytes and CD4/CD8 ratio were lower than those of the sarcoidosis group[(11.71±6.64)% vs. (23.30±12.68)%,(1.46±0.83) vs. (4.01±5.10),P<0.05]. In the IPF group,the level of KL-6 in the BALF and serum was higher than that of the arcoidosis group[(437.43±251.70) U/mL vs. (221.59±127.41) U/mL,(857.81±515.53) U/mL vs. (338.67±168.13) U/mL,P<0.001]. There was obvious correlation between the level of serum KL-6 with FVC%pred and DLCO%pred in the IPF group (r=-0.46,r=-0.58,P<0.05).
Conclusions The level of KL-6 in BALF and serum is elevated in patients with IPF. There is obvious correlation between the level of serum KL-6 with FVC%pred and DLCO%pred in IPF patients. KL-6 may be an indicator of IPF in clinical diagnose.
Citation：
ZhuChen, ZhaoYabin, KongLingfei, LiZhenhua, KangJian. Expression and Significance of KL-6 in BALF and Serum of Patients with Idiopathic Pulmonary Fibrosis. Chinese Journal of Respiratory and Critical Care Medicine, 2015, 14(3): 225-228. doi: 10.7507/1671-6205.2015058
Copy
Copyright © the editorial department of Chinese Journal of Respiratory and Critical Care Medicine of West China Medical Publisher. All rights reserved
| 1. |
Panos RJ,Mortenson RL,Niccoli SA,et al. Clinical deterioration in patients with idiopathic pulmonary fibrosis:causes and assessment. Am J Med,1990,88:396-404.
|
| 2. |
Olson AL,Swigris JJ,Lezotte DC,et al. Mortality from pulmonary fibrosis increased in the United States from 1992 to 2003. Am J Respir Crit Care Med,2007,176:277-284.
|
| 3. |
Kohno N,Kyoizumi S,Awaya Y,et al. New serum indicator of interstitial pneumonitis activity. Sialylated carbohydratel antigen KL-6. Chest,1989,96:68-73.
|
| 4. |
Ohshimo S,Yokoyama A,Hattori N,et al.KL-6,a human MUC1 mucin,promotes proliferation and survival of lung fibrosis.Biochem Biophys Res Commun,2005,338:1845-1852.
|
| 5. |
Raghu G,Collard HR,Egan JJ,et al. An official ATS/ERS/JRS/ALAT statement:idiopathic pulmonary fibrosis:evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med,2011,183:788-824.
|
| 6. |
中华医学会呼吸病学分会.支气管肺泡灌洗液细胞学检测技术规范(草案).中华结核和呼吸杂志,2002,25:390-391.
|
| 7. |
魏丽,马艳良,高占成,等.黏蛋白和间质性肺疾病.中华结核和呼吸杂志,2012,35:700-702.
|
| 8. |
Xu L,Yan DR,Zhu SL,et al. KL-6 regulated the expression of HGF,collagen and myofibroblastdifferentiation. Eur Rev Med Pharmacol Sci,2013,17:3073-3077.
|
| 9. |
Kitamura S,Hiwada K,Kobayashi J,et al. Use of the ED046 kit to analyze serum KL-6 in patients with pneumonitis. Nihon Kyobu Shikkan Gakkai Zasshi,1996,34:639-645.
|
| 10. |
Kohno N. Serum marker KL-6/MUC1 for the diagnosis and management of interstitial pneumonitis. J Med Invest,1999,46:151-158.
|
| 11. |
日本呼吸学会弥漫性肺疾患的诊断·治疗指南编制委员会.特发性间质性肺病诊断和治疗手册. 日本呼吸器学会杂志,2011,43:179-207.
|
- 1. Panos RJ,Mortenson RL,Niccoli SA,et al. Clinical deterioration in patients with idiopathic pulmonary fibrosis:causes and assessment. Am J Med,1990,88:396-404.
- 2. Olson AL,Swigris JJ,Lezotte DC,et al. Mortality from pulmonary fibrosis increased in the United States from 1992 to 2003. Am J Respir Crit Care Med,2007,176:277-284.
- 3. Kohno N,Kyoizumi S,Awaya Y,et al. New serum indicator of interstitial pneumonitis activity. Sialylated carbohydratel antigen KL-6. Chest,1989,96:68-73.
- 4. Ohshimo S,Yokoyama A,Hattori N,et al.KL-6,a human MUC1 mucin,promotes proliferation and survival of lung fibrosis.Biochem Biophys Res Commun,2005,338:1845-1852.
- 5. Raghu G,Collard HR,Egan JJ,et al. An official ATS/ERS/JRS/ALAT statement:idiopathic pulmonary fibrosis:evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med,2011,183:788-824.
- 6. 中华医学会呼吸病学分会.支气管肺泡灌洗液细胞学检测技术规范(草案).中华结核和呼吸杂志,2002,25:390-391.
- 7. 魏丽,马艳良,高占成,等.黏蛋白和间质性肺疾病.中华结核和呼吸杂志,2012,35:700-702.
- 8. Xu L,Yan DR,Zhu SL,et al. KL-6 regulated the expression of HGF,collagen and myofibroblastdifferentiation. Eur Rev Med Pharmacol Sci,2013,17:3073-3077.
- 9. Kitamura S,Hiwada K,Kobayashi J,et al. Use of the ED046 kit to analyze serum KL-6 in patients with pneumonitis. Nihon Kyobu Shikkan Gakkai Zasshi,1996,34:639-645.
- 10. Kohno N. Serum marker KL-6/MUC1 for the diagnosis and management of interstitial pneumonitis. J Med Invest,1999,46:151-158.
- 11. 日本呼吸学会弥漫性肺疾患的诊断·治疗指南编制委员会.特发性间质性肺病诊断和治疗手册. 日本呼吸器学会杂志,2011,43:179-207.
1/5
WeChat
